产品
编 号：F358598
分子式：C36H45N3O7S2
分子量：695.89
分子式：C36H45N3O7S2
分子量：695.89
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 439087-18-0
产品详情
生物活性：
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
体内研究：
Elobixibat (每天口服 0.27 mg/kg，持续 20 周) 通过抑制胆汁酸重吸收并降低血清和肝脏中总胆汁酸和初级胆汁酸水平来抑制脂肪肝小鼠模型中的肿瘤生长。Elobixibat (每周 5 天，每天 0.2, 0.6, or 1.2 mg/kg，管饲法 gavage) 可改善非脂肪性肝炎 (NASH) 小鼠模型中 NASH 相关的组织病理学，降低细胞因子 (TNF-α，IL-6 和 TGF-β) 表达，并使肠道微生物组成正常化。Animal Model:Mouse Model of Nonalcoholic Steatohepatitis (three-week-old male C57BL/6J mice)
Dosage:0.27 mg/kg/day for 20 weeks
Administration:p.o.
Result:Reduced the number and size of tumors.Significantly reduced the number of Gram-positive bacteria in the phyla Firmicutes, Deferobacteria and Actinobacteria and increased the number of Proteobacteria.
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
体内研究：
Elobixibat (每天口服 0.27 mg/kg，持续 20 周) 通过抑制胆汁酸重吸收并降低血清和肝脏中总胆汁酸和初级胆汁酸水平来抑制脂肪肝小鼠模型中的肿瘤生长。Elobixibat (每周 5 天，每天 0.2, 0.6, or 1.2 mg/kg，管饲法 gavage) 可改善非脂肪性肝炎 (NASH) 小鼠模型中 NASH 相关的组织病理学，降低细胞因子 (TNF-α，IL-6 和 TGF-β) 表达，并使肠道微生物组成正常化。Animal Model:Mouse Model of Nonalcoholic Steatohepatitis (three-week-old male C57BL/6J mice)
Dosage:0.27 mg/kg/day for 20 weeks
Administration:p.o.
Result:Reduced the number and size of tumors.Significantly reduced the number of Gram-positive bacteria in the phyla Firmicutes, Deferobacteria and Actinobacteria and increased the number of Proteobacteria.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备